Jana Albrecht

Title: Jana Albrecht: Innovator in Antibody Research

Introduction

Jana Albrecht is a prominent inventor based in Frankfurt-am-Main, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of antibody-like binding proteins. Her work focuses on innovative solutions for cancer treatment.

Latest Patents

Jana Albrecht holds a patent for "Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123." This invention involves antibody-like binding proteins that specifically bind to CD3 and at least one other antigen, such as CD123. The patent also covers anti-CD3 and anti-CD123 antibodies, along with pharmaceutical compositions that utilize these proteins for cancer treatment. Additionally, the invention includes isolated nucleic acids, vectors, and host cells that encode these antibodies, highlighting their potential as diagnostic tools.

Career Highlights

Jana Albrecht is currently employed at Sanofi, a global healthcare company. Her role involves extensive research and development in the field of antibody therapies. With her innovative approach, she has contributed to advancing therapeutic options for patients suffering from cancer.

Collaborations

Jana collaborates with notable colleagues, including Cédric Barriere and Christian Beil. Their combined expertise enhances the research efforts at Sanofi, fostering an environment of innovation and discovery.

Conclusion

Jana Albrecht's work in antibody research exemplifies the impact of innovation in biotechnology. Her contributions are paving the way for new cancer treatments, showcasing the importance of scientific advancement in healthcare.